Organogenesis Holdings is a regenerative medicine company engaged on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical and Sports Medicine markets. In the Advanced Wound Care market, Co. engages on the development and commercialization of a portfolio of cellular and acellular wound care offerings that treat patients from the earliest indication of impaired healing to wound closure. In the Surgical and Sports Medicine market, Co. engages on the development and commercialization of products that support the healing of musculoskeletal injuries, including chronic degenerative conditions such as osteoarthritis and tendonitis. The ORGO average annual return since 2017 is shown above.
The Average Annual Return on the ORGO average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ORGO average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ORGO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|